Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

NCT00005031 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NETWORK

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: irofulven

Sponsor

Gynecologic Oncology Group

Collaborators

[object Object]